Co-occurring driver mutations in BRAF-positive NSCLC have been described with rates up to 13%, including KRAS (previously considered mutually exclusive), EGFR mutations, ALK fusions, ROS1 fusions, HER2 amplifications, and MET alterations. This evidence concerns the gene BRAF and non-small cell lung carcinoma.